血清 HBcrAg 在核苷（酸）类似物治疗 8 年的慢性乙型肝炎患者中的表现。

Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy.

机构信息

Center of infectious diseases, West China hospital, Sichuan university, Chengdu 610041, P.R. China; Department of laboratory medicine, West China hospital, Sichuan university, Chengdu 610041, P.R. China.

出版信息

Clin Res Hepatol Gastroenterol. 2019 Jun;43(3):301-309. doi: 10.1016/j.clinre.2018.10.020. Epub 2018 Nov 27.

DOI:10.1016/j.clinre.2018.10.020

PMID:30497844

Abstract

AIM

This study aimed to investigate long-term kinetics of serum hepatitis B core-related antigen (HBcrAg) and its correlation with serum hepatitis B surface antigen (HBsAg) in a real-world cohort of patients who had received over 8 years of nucleos(t)ide analogs(NAs) therapy.

METHODS

This was a retrospective study. All patients were recruited from our previous published study, who started therapy with NAs between 2007 and 2008. Serum HBcrAg and HBsAg levels were quantitatively measured at baseline, the sixth month and each year of follow-up, using the stored serum samples.

RESULTS

Among the 94 patients, serum HBcrAg presented a gradually decreasing trend from baseline to year 8, either in HBeAg-negative or HBeAg-positive patients. After 8 years of NAs treatment, 21.3% of patients achieved serum HBcrAg < 3 log 10 U/mL, and only baseline HBcrAg was an independent predictor. Additionally, good correlation of HBcrAg and HBsAg was observed at baseline, but this correlation weakened remarkably during treatment.

CONCLUSION

Serum HBcrAg is decreasing gradually with the duration of antiviral therapy, and baseline HBcrAg level is an independent predictor of long-term HBcrAg below the limit of detection.

摘要

目的

本研究旨在探究接受核苷（酸）类似物（NAs）治疗超过 8 年的真实世界患者中血清乙型肝炎核心相关抗原（HBcrAg）的长期动力学及其与血清乙型肝炎表面抗原（HBsAg）的相关性。

方法

这是一项回顾性研究。所有患者均来自我们之前发表的研究，他们于 2007 年至 2008 年期间开始 NAs 治疗。使用储存的血清样本在基线、第 6 个月和随访的每年定量测量血清 HBcrAg 和 HBsAg 水平。

结果

在 94 例患者中，无论是 HBeAg 阴性还是 HBeAg 阳性患者，血清 HBcrAg 均从基线呈逐渐下降趋势，至第 8 年。经过 8 年的 NAs 治疗，21.3%的患者达到血清 HBcrAg<3 log 10 U/mL，且仅基线 HBcrAg 是独立预测因素。此外，在基线时观察到 HBcrAg 与 HBsAg 具有良好的相关性，但在治疗过程中这种相关性显著减弱。